TITLE

What Next After Infliximab?

AUTHOR(S)
Baidoo, Leonard; Lichtenstein, Gary R.
PUB. DATE
January 2005
SOURCE
American Journal of Gastroenterology;Jan2005, Vol. 100 Issue 1, p80
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The use of infliximab (Remicade®) has revolutionized the care of Crohn's disease (CD) patients who have proved refractory to standard treatment. The use of infliximab is very well tolerated in the majority of patients but in a small subset of patients may lead to the production of antibodies (termed“antibodies to infliximab”—ATI). The production of these antibodies has been associated with the development of both acute and delayed infusion reactions, although even in patients who develop ATIs, these reactions are relatively uncommon. Nonetheless, these reactions may occasionally be severe enough to lead to intolerance to infliximab. Another group of patients, after initially having excellent responses to infliximab, experience an attenuated response or loss of response over time. What is the cause of this loss of efficacy? ATIs may play a role in some patients but other potential reasons for this phenomenon have provoked much debate. The importance of other cytokines after TNF-α has been neutralized may be relevant as (this has been shown to be the case in rheumatoid arthritis (RA) is the idea of beneficial autoimmunity production to TNF-α. (Wildbaum G, Nahir MA, Karin N. Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. Immunity 2003;19:679–88.) It has been shown that during the course of an autoimmune condition, the immune system mounts a beneficial autoantibody response to proinflammatory mediators. This response counteracts, to a certain degree, the autoimmune pathology. This natural counteraction has been illustrated in animal models of autoimmunity, and there has been evidence demonstrated that this occurs in human RA. Whether this occurs in Crohn's is unknown; infliximab is a chimeric monoclonal antibody containing an approximately 25% murine region. It had been hoped that the development of humanized or fully human monoclonal antibodies would provide therapeutic antibodies that did not induce an immune response. While this has unfortunately not proven to be the case—these products still have significant immunogenicity—these products do present an alternative therapy when infliximab cannot be used. In light of this, adalimumab (Humira®) a human monoclonal antibody used for treating rheumatologic conditions has been investigated as an alternate treatment for patients with CD who after initially responding to infliximab experience intolerance or loss of efficacy. Is this a viable alternative?(Am J Gastroenterol 2005;100:80–83)
ACCESSION #
15416351

 

Related Articles

  • Etanercept and infliximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis. Fusconi, Marco; Vannini, Antonio; Dall’Aglio, Anna Chiara; Pappas, Georgios; Bianchi, Francesco B.; Zauli, Daniela // Rheumatology International;Nov2007, Vol. 28 Issue 1, p47 

    Etanercept and infliximab treatments are often associated with autoantibodies induction. Their reported prevalences vary among different studies and the conclusions are somehow conflicting, mainly regarding whether the two drugs induce the same modifications. In this small prospective study,...

  • Perianal Crohn's disease and infliximab therapy. McNamara, D. A.; Brophy, S.; Hyland, J. M. P. // Surgeon (Edinburgh University Press);Oct2004, Vol. 2 Issue 5, p258 

    Introduction: Perianal manifestations occur in almost half of patients with Crohn's disease and often respond poorly to conventional therapies. The introduction of anti-tumour necrosis factor alpha agents (e.g. infliximab) has altered the management of patients who fail first and second line...

  • New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. Tanno, Makoto; Nakamura, Ichiro; Kobayashi, Shunsuke; Kurihara, Kumiko; Ito, Katsumi // Clinical Rheumatology;Dec2006, Vol. 25 Issue 6, p929 

    Therapies aimed at inhibiting tumor necrosis factor, a proinflammatory cytokine implicated in autoimmune disease, are effective for rheumatoid arthritis (RA) and Crohn’s disease. We report two patients who newly developed multiple demyelinating lesions in the central nervous system in the...

  • Human Tears Reveal Insights into Corneal Neovascularization. Zakaria, Nadia; Grasdorff, Sigi Van; Wouters, Kristien; Rozema, Jos; Koppen, Carina; Lion, Eva; Cools, Nathalie; Berneman, Zwi; Tassignon, Marie-José // PLoS ONE;May2012, Vol. 7 Issue 5, p1 

    Corneal neovascularization results from the encroachment of blood vessels from the surrounding conjunctiva onto the normally avascular cornea. The aim of this study is to identify factors in human tears that are involved in development and/ or maintenance of corneal neovascularization in humans....

  • Reassessment of CXCR4 Chemokine Receptor Expression in Human Normal and Neoplastic Tissues Using the Novel Rabbit Monoclonal Antibody UMB-2. Fischer, Thomas; Nagel, Falko; Jacobs, Stefan; Stumm, Ralf; Schulz, Stefan // PLoS ONE;2008, Vol. 3 Issue 12, p1 

    Background: The CXCR4 chemokine receptor regulates migration and homing of cancer cells to specific metastatic sites. Determination of the CXCR4 receptor status will provide predictive information for disease prognosis and possible therapeutic intervention. However, previous attempts to localize...

  • Potential therapeutic role for cytokine or adhesion molecule manipulation in Crohn's disease: in the shadow of infliximab? Shand, Alan; Forbes, Alastair // International Journal of Colorectal Disease;Jan2003, Vol. 18 Issue 1, p1 

    Background. Inappropriate activation of the intestinal immune system leading to a persistent inflammatory response is implicated in the pathogenesis of both Crohn's disease and ulcerative colitis. Various cytokines and cell surface molecules expressed by immunologically active cells are involved...

  • A transforming growth factor-β1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura. Andersson, P. O.; Stockelberg, D.; Jacobsson, S.; Wadenvik, H. // Annals of Hematology;Sep2000, Vol. 79 Issue 9, p507 

    Bystander immune suppression has been demonstrated in experimental models of oral immune tolerance induction. This phenomenon is associated with expression of transforming growth factor (TGF)-β1 and T-helper cell (Th) 2 cytokines. We have studied serum levels of Th cytokines and B- and...

  • Altered production of immunoregulatory cytokines by invariant V{alpha}19 TCR-bearing cells dependent on the duration and intensity of TCR engagement. Michio Shimamura; Yi-Ying Huang; Masumi Kobayashi; Hiroshi Goji // International Immunology;Feb2009, Vol. 21 Issue 2, p179 

    Cells bearing invariant Vα19-Jα33 TCR α chains are believed to participate in the regulation of inflammatory autoimmune diseases. In this study, the potential to produce immunoregulatory cytokines by these cells was characterized in order to find the mechanism underlying their...

  • The Use of Infliximab in Dermatology. Demirtaşoğlu, Melda; Fetil, Emel // Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry;Aug2007, Vol. 6 Issue 3, p188 

    Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-α) which is major cytokine playing pivotal role in inflammatory diseases. Efficacy and safety of infliximab was studied in numerous inflammatory skin diseases where TNF-α is involved in pathogenesis...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics